last (full) session of the year

    last (full) session of the year

    The trend is hesitant in view of the last full session of the year on the Paris Stock Exchange since that of tomorrow 12/31 will end at 2 p.m. Yesterday evening, the New York Stock Exchange closed slightly, the day after new records for its main indices, in a still “light” trading volume. The markets are divided between the good news, including the new $ 900 billion stimulus plan in the United States, the post-#Brexit agreement and the start of mass vaccination against Covid-19, and the health situation which continues to deteriorate rapidly on both sides of the Atlantic.

    WALL STREET

    At the close, the Dow Jones index lost 0.22% to 30,335 points, while the large S&P 500 index fell 0.22% to 3,727 pts, and the Nasdaq Composite index, rich in technology stocks and biotechs, dropped 0.38% to 12,850 pts. Intel shares jumped 4.9% on Wall Street after reports that activist investor Daniel Loeb took a stake and is pushing for a strategic evolution of the microprocessor maker …

    ECO AND CURRENCIES

    In the United States, markets were relieved Monday by the final adoption of the new US budget plan of $ 892 billion, which provides for the payment of direct aid of $ 600 to Americans, as well as unemployment benefits for about 14 million unemployed and aid to SM#Es (financing of technical unemployment).
    The text was passed by Congress on December 22, then ratified on Sunday by Donald Trump, who initially refused to sign it, demanding that direct aid to American households be increased from $ 600 to $ 2,000. A request that was greeted with enthusiasm by the Democrats, but was blocked by the Republicans …
    Thus, on Monday evening, the House of Representatives, with a Democratic majority, adopted a text increasing the aid checks from $ 600 to $ 2000 … The two-thirds majority, necessary for this vote, could be achieved thanks to the contribution of 44 Republican votes. But the leader of the Republican majority in the Senate, Mitch Mc#Connell, refused Tuesday evening to hold a vote on the project. He linked any Senate vote on the issue to two other sensitive issues: protection of internet giants against legal actions and an investigation into possible electoral irregularities. Conditions that risk torpedoing the project …

    Oil prices started to rise again, taking advantage of the weak dollar, which offset fears about demand and the resurgence of Covid-19 in the United States and Europe. US WTI light crude oil price rallied 0.85% to $ 48.30 per barrel for January Nymex futures contract, while February North Sea Brent peaked at 51.35 $. Gold is trading at $ 1,878 an ounce in London. The euro remains firm at 1.2280 / $.

    TO WATCH ON THE AGENDA

    ECONOMIC INDICATORS:
    United States :
    – Balance of trade in goods. (2:30 p.m.)
    – Stocks and wholesale sales. (2:30 p.m.)
    – Chicago Manufacturing PMI Index. (3:45 p.m.)
    – Promises of home sales. (4:00 p.m.)
    – Weekly report from the Department of Energy on domestic oil stocks. (4.30 p.m.)

    Europe :
    – Spanish consumer price flash index. (09h00)

    VALUES TO FOLLOW

    CGG announces the conversion on December 29, 2020, of a “Seller Credit” issued by Shearwater Geoservices Holding AS (SGS) “Shearwater”, on January 8, 2020 for an amount of US $ 49,399,176 into a participation in SGS.
    As part of this transaction, CGG subscribed for 1,958,248 Class A shares, which corresponds to 3.30% of the total outstanding shares and 3.34% of the SGS shares holding voting rights.

    Argan, the only listed French real estate company specializing in the development of PREMIUM logistics warehouses, announces the acquisition of a portfolio of two logistics platforms totaling 128,000 m (2).

    Realities: 49 managers contributed 10 ME in the capital, which represents the most important fundraising ever carried out among its executives by a company in the sector.
    With the support of Banque Palatine and BRED, 49 managers out of 90 solicited came together within the company Grand R, endowed with 10 ME, 7 ME contributed by the executives and 3 ME by a loan which is divided up of 4.87 ME in the capital of Réalités and 4.8 ME in respect of a TSSDI bond on Réalités.
    This capital increase, in addition to that carried out by the founders in July for a little less than 15 ME, strengthens the Group’s equity.

    Groupe Open: The founders of the group and Montefiore Investment announce the reopening of the takeover bid for the capital of Groupe Open from December 29, 2020 until January 13, 2021 (inclusive).
    The reopened offer will allow Groupe Open shareholders who have not tendered their shares to do so, at the same price, ie 15 euros per share. At the end of the Offer, which closed on December 17, 2020, the members of the concert held 71.71% of the capital and 77.08% of the voting rights of Groupe Open.
    The Offeror reserves the right to acquire Groupe Open shares on the market at the offer price of 15 euros per share, from December 29, 2020 to January 13, 2021 inclusive. Portzamparc (BNP Paribas), acting as a buying market member on behalf of the Offeror, will acquire the shares on the market, if applicable.

    Noxxon Pharma NV, a biotechnology company specializing in the development of improved cancer treatments targeting the tumor microenvironment (MET), announces the start of production of NOX-A12, the Company’s flagship product, in anticipation of its future clinical studies.
    As indicated in previous communications, NOXXON’s clinical development strategy for NOX-A12 focuses on two oncological indications: brain cancer and pancreatic cancer. The Company intends to evaluate several therapeutic combinations in order to develop NOX-A12 and the Company’s product portfolio in indications with high medical need and for which very few treatments exist.
    Regarding pancreatic cancer, NOXXON will launch its two-arm clinical trial in the second half of 2021. This study will evaluate two distinct combinations of standard chemotherapy with NOX-A12 and anti-PD-1 immunotherapy in second-line patients. This strategic approach will allow NOXXON to determine the most effective combination therapy for the launch of a pivotal, controlled and randomized study.

    Share Button